PureTech Health Quote - PRTC

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

18.95

Bid

18.33

Offer

19.40

Volume

4,149

18.06 Day's Range 19.51

0.00 52 Week Range 0.00

Market Cap

453.703M

Previous Close

18.95

Open

18.61

Last Trade

18.66

Last Trade Time

Financial Volume

US$ 78,923

VWAP

19.0223

Average Volume (3m)

Shares Outstanding

23,942,131

Dividend Yield

PE Ratio

-0.53

Earnings Per Share (EPS)

-2.74

Revenue

65.12M

Net Profit

-65.7M

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines ... PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, neurological & neuropsychological disorders, among others. It operates in following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept, focused on addressing some of society's healthcare needs. Show more

Sector

Home Health Care Services

Industry

Home Health Care Services

Website

www.puretechhealth.com

Headquarters

London, Gbr

Founded

PureTech Health PLC is listed in the Home Health Care Services sector of the NASDAQ with ticker PRTC. The last closing price for PureTech Health was US$18.95. Over the last year, PureTech Health shares have traded in a share price range of US$ 0.00 to US$ 0.00.

PureTech Health currently has 23,942,131 shares in issue. The market capitalisation of PureTech Health is US$453.70 million. PureTech Health has a price to earnings ratio (PE ratio) of -0.53.

PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform

Published data shows new site of Glyph prodrug attachment demonstrated highest reported level of lymphatic transport to date of the studied...

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms Analyses identified predictors of VE303 colonization and...

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients...

PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the...

PureTech Appoints UBS as UK Corporate Broker

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate...

PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

Dose-ranging trial evaluated deupirfenidone 550 mg three times a day (TID) (approximately equivalent exposure to pirfenidone 801 mg TID1) and...

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024

Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included in a planned Phase 2b study in major depressive...

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

LYT-200 is generally safe and well-tolerated as a single agent as well as in combination with standard-of-care venetoclax and hypomethylating...

PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors

Lead Independent Director at Microsoft and former Group Worldwide Chair for Johnson & Johnson brings extensive experience in life sciences...

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

PRTC - Frequently Asked Questions (FAQ)

What is the current PureTech Health share price?

The current share price of PureTech Health is US$ 18.95

How many PureTech Health shares are in issue?

PureTech Health has 23,942,131 shares in issue

What is the market cap of PureTech Health?

The market capitalisation of PureTech Health is USD 453.7M

What is the 1 year trading range for PureTech Health share price?

PureTech Health has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of PureTech Health?

The price to earnings ratio of PureTech Health is -0.53

What is the cash to sales ratio of PureTech Health?

The cash to sales ratio of PureTech Health is 0.53

What is the reporting currency for PureTech Health?

PureTech Health reports financial results in USD

What is the latest annual turnover for PureTech Health?

The latest annual turnover of PureTech Health is USD 65.12M

What is the latest annual profit for PureTech Health?

The latest annual profit of PureTech Health is USD -65.7M

What is the registered address of PureTech Health?

The registered address for PureTech Health is C/O TMF GROUP, 13TH FLOOR, ONE ANGEL COURT, LONDON, EC2R 7HJ

What is the PureTech Health website address?

The website address for PureTech Health is www.puretechhealth.com

Which industry sector does PureTech Health operate in?

PureTech Health operates in the HOME HEALTH CARE SERVICES sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
JTAIJet AI Inc	US$ 6.02 (133.33%)	104.48M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	254.39M
WRDWeRide Inc	US$ 31.4877 (83.39%)	21.07M
INLFINLIF Limited	US$ 16.27 (80.58%)	7.68M
MBRXMoleculin Biotech Inc	US$ 2.1201 (66.94%)	136.66M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3.08 (-56.31%)	425.19k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3.36 (-52.68%)	5.21k
CSAICloudastructure Inc	US$ 19.0001 (-49.58%)	1.01M
NEXNNexxen International Ltd	US$ 10.30 (-49.16%)	160.99k
BSLKBolt Projects Holdings Inc	US$ 0.6626 (-46.13%)	13.07M
CNSPCNS Pharmaceuticals Inc	US$ 0.1415 (31.26%)	480.49M
MGOLMGO Global Inc	US$ 0.7176 (-15.08%)	411.17M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	248.48M
INTCIntel Corporation	US$ 23.60 (-2.20%)	225.04M
NVDANVIDIA Corporation	US$ 138.85 (2.63%)	189.56M